BridgeBio Pharma (BBIO) Profit After Tax (2018 - 2026)

BridgeBio Pharma has reported Profit After Tax for 9 years, with the latest figure at -$166.6 million in Q1 2026.

• Quarterly Profit After Tax rose 1.8% year-over-year to -$166.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$729.9 million (down 7.84% YoY) and the FY2025 annual result came in at -$732.9 million, down 34.89% from the prior year.
• Profit After Tax advanced to -$166.6 million in Q1 2026 per BBIO's latest filing, from -$194.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$2.6 million in Q2 2022 and troughed at -$267.4 million in Q4 2024.
• A 5-year average of -$151.8 million and a median of -$166.6 million in 2026 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax jumped 97.49% in 2022, then tumbled 6179.91% in 2023.
• Over 5 years, Profit After Tax stood at -$140.6 million in 2022, then fell by 21.17% to -$170.3 million in 2023, then slumped by 56.98% to -$267.4 million in 2024, then advanced by 27.21% to -$194.6 million in 2025, then advanced by 14.43% to -$166.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$166.6 million, -$194.6 million, and -$184.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.